Cell Source Stock Performance
| CLCS Stock | USD 0.89 0.01 1.14% |
Cell Source holds a performance score of 18 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.29, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cell Source will likely underperform. Use Cell Source sortino ratio and the relationship between the downside variance and market facilitation index , to analyze future returns on Cell Source.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Cell Source are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile fundamental indicators, Cell Source unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 245.1 K | |
| Free Cash Flow | -3.4 M |
Cell |
Cell Source Relative Risk vs. Return Landscape
If you would invest 38.00 in Cell Source on November 3, 2025 and sell it today you would earn a total of 51.00 from holding Cell Source or generate 134.21% return on investment over 90 days. Cell Source is currently generating 1.6307% in daily expected returns and assumes 6.8533% risk (volatility on return distribution) over the 90 days horizon. In different words, 61% of pink sheets are less volatile than Cell, and 68% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cell Source Target Price Odds to finish over Current Price
The tendency of Cell Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.89 | 90 days | 0.89 | about 1.51 |
Based on a normal probability distribution, the odds of Cell Source to move above the current price in 90 days from now is about 1.51 (This Cell Source probability density function shows the probability of Cell Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 1.29 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Cell Source will likely underperform. Moreover Cell Source has an alpha of 1.4999, implying that it can generate a 1.5 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Cell Source Price Density |
| Price |
Predictive Modules for Cell Source
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cell Source. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cell Source's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cell Source Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cell Source is not an exception. The market had few large corrections towards the Cell Source's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cell Source, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cell Source within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.50 | |
β | Beta against Dow Jones | 1.29 | |
σ | Overall volatility | 0.18 | |
Ir | Information ratio | 0.23 |
Cell Source Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cell Source for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cell Source can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cell Source is way too risky over 90 days horizon | |
| Cell Source has some characteristics of a very speculative penny stock | |
| Cell Source appears to be risky and price may revert if volatility continues | |
| Cell Source currently holds 6.5 M in liabilities. Cell Source has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cell Source until it has trouble settling it off, either with new capital or with free cash flow. So, Cell Source's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cell Source sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cell to invest in growth at high rates of return. When we think about Cell Source's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cell Source currently holds about 93.09 K in cash with (3.38 M) of positive cash flow from operations. | |
| Roughly 32.0% of the company shares are held by company insiders |
Cell Source Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cell Pink Sheet often depends not only on the future outlook of the current and potential Cell Source's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cell Source's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 29.1 M | |
| Short Long Term Debt | 6.5 M | |
| Cash And Short Term Investments | 93.1 K | |
| Shares Float | 24.5 M |
Cell Source Fundamentals Growth
Cell Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Cell Source, and Cell Source fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cell Pink Sheet performance.
| Return On Asset | -3.78 | |||
| Current Valuation | 59.65 M | |||
| Shares Outstanding | 35.25 M | |||
| Price To Earning | (3.28) X | |||
| EBITDA | (4.11 M) | |||
| Cash And Equivalents | 93.09 K | |||
| Total Debt | 6.5 M | |||
| Debt To Equity | (1.04) % | |||
| Book Value Per Share | (0.34) X | |||
| Cash Flow From Operations | (3.38 M) | |||
| Earnings Per Share | (0.20) X | |||
| Total Asset | 313.77 K | |||
| Retained Earnings | (21.7 M) | |||
| Current Asset | 213.56 K | |||
| Current Liabilities | 8 M | |||
About Cell Source Performance
Assessing Cell Source's fundamental ratios provides investors with valuable insights into Cell Source's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cell Source is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.Things to note about Cell Source performance evaluation
Checking the ongoing alerts about Cell Source for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Cell Source help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cell Source is way too risky over 90 days horizon | |
| Cell Source has some characteristics of a very speculative penny stock | |
| Cell Source appears to be risky and price may revert if volatility continues | |
| Cell Source currently holds 6.5 M in liabilities. Cell Source has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cell Source until it has trouble settling it off, either with new capital or with free cash flow. So, Cell Source's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cell Source sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cell to invest in growth at high rates of return. When we think about Cell Source's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Cell Source currently holds about 93.09 K in cash with (3.38 M) of positive cash flow from operations. | |
| Roughly 32.0% of the company shares are held by company insiders |
- Analyzing Cell Source's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cell Source's stock is overvalued or undervalued compared to its peers.
- Examining Cell Source's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cell Source's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cell Source's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cell Source's pink sheet. These opinions can provide insight into Cell Source's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cell Pink Sheet Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.